Table 1

Baseline details of patients in both arms

VariableArm A (gefitinib arm)Arm B (pemetrexed–platinum arm)
Mean age 54.44 years 53.12 years
Elderly status (≥65 years)
Gender
Male 67 (46.2%) 97 (66.9%)
Female 78 (53.8%) 48 (33.1%)
Smoking status
Never smoker113 (77.9%)117 (80.7%)
Ex-smoker 32 (22.1%) 28 (19.3%)
Tobacco habit status
Present 52 (35.9%) 59 (40.7%)
Absent 93 (64.1%) 86 (59.3%)
ECOG PS
PS-0  3 (2.1%)  2 (1.4%)
PS-1132 (91.0%)136 (93.8%)
PS-2 10 (6.9%)  7 (4.8%)
Stage
3  2 (1.4%)  3 (2.1%)
4143 (98.6%)142 (97.9%)
Presence of brain metastasis 22 (15.7%) 23 (15.9%)
Presence of liver metastasis 35 (24.1%) 40 (27.6%)
EGFR mutation status Exon 18 (G719C point mutation)  4 (2.8%)  2 (1.4%)
Exon 19 76 (52.4%) 92 (63.4%)
Exon 21 65 (44.8%) 51 (35.2%)
  • ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.